AU2019200301B2 — Novel methods
Assigned to Intra Cellular Therapies Inc · Expires 2020-01-30 · 6y expired
What this patent protects
A long-acting injectable composition comprising polymeric microspheres comprising a PLGA matrix with either carboxylic acid or carboxylic ester end groups, and an effective amount of a 5 Compound of Formula I, the Compound of Formula I being dispersed, dissolved or encapsulate…
USPTO Abstract
A long-acting injectable composition comprising polymeric microspheres comprising a PLGA matrix with either carboxylic acid or carboxylic ester end groups, and an effective amount of a 5 Compound of Formula I, the Compound of Formula I being dispersed, dissolved or encapsulated in the polymer matrix of the microsphere: F H NN X ) Formula I wherein: X is -0-, -NH- or -N(CH3)-; 10 Y is -0-, -C(R2)(OH)-, -C(R3)(OR1) or -C(O)-; R 1 is -C1.6 alkyl or -C(O)-C-21alkyl optionally saturated or unsaturated and optionally substituted with one or more hydroxy or Ci-22alkoxy groups, wherein such compound hydrolyzes to form the residue of a natural or unnatural, saturated or unsaturated fatty acid; 15 R2 is H or -CI 6 alkyl; and R3 is H or -C 6 alkyl; in free or pharmaceutically acceptable salt form.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.